The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 12 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [ENERGITO® 2]

The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with fluticasone propionate+salmeterol fixed dose combination over 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD).

A Digital Health (DH) exploratory study has been integrated into the main study as a site specific study. The DH exploratory study will be performed at a single site; the site is also participating in the main study. The DH exploratory study site will enter (randomize) approximately 20 patients (subjects) (in addition to the patients to be enrolled in the main study at this site). The patients enrolled in the DH exploratory study are not considered to be part of the main study (i.e. data collected in the DH exploratory study will be analyzed separately from the data collected in the main study).

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Drug: Tiotropium; Drug: Olodaterol; Drug: Fluticasone propionate; Drug: Salmeterol

• Study Type: Interventional
• Enrollment (Actual): 302
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Jasper, Alabama, United States, 35501
      • Jasper Summit Research, LLC
  • Arizona
    • Flagstaff, Arizona, United States, 86001
      • Clinical Trial Connection
  • California
    • Fullerton, California, United States, 92835
      • California Research Medical Group, Inc.
    • Huntington Beach, California, United States, 92647
      • Allergy and Asthma Specialists Medical Group
    • Northridge, California, United States, 91324
      • California Medical Research Associates Inc.
  • Colorado
    • Centennial, Colorado, United States, 80112
      • IMMUNOe Research Centers
  • Florida
    • Clearwater, Florida, United States, 33765
      • Clinical Research of West Florida, Inc.
    • Orlando, Florida, United States, 32806
      • Bioclinica Research
    • Palmetto Bay, Florida, United States, 33157
      • IMIC, Inc
    • Tampa, Florida, United States, 33603
      • Clinical Research of West Florida, Inc.
  • Georgia
    • Duluth, Georgia, United States, 30096
      • Duluth Biomedical Research
    • Marietta, Georgia, United States, 30060
      • DC Pulmonary Medicine
  • Louisiana
    • New Orleans, Louisiana, United States, 70119
      • New Orleans Center for Clinical Research
  • Maryland
    • Baltimore, Maryland, United States, 21224
      • Johns Hopkins Hospital
  • Michigan
    • Farmington Hills, Michigan, United States, 48336
      • Pulmonary Rsrch Inst of SE MI
  • Minnesota
    • Edina, Minnesota, United States, 55435
      • Minnesota Lung Center and Sleep Institute
    • Minneapolis, Minnesota, United States, 55402
      • Clinical Research Institute Inc
    • Woodbury, Minnesota, United States, 55125
      • Minnesota Lung Center
  • Missouri
    • Saint Louis, Missouri, United States, 63141
      • The Clinical Research Center, LLC
  • New York
    • New Hyde Park, New York, United States, 11040
      • Northwell Health
  • North Carolina
    • Gastonia, North Carolina, United States, 28054
      • Gastonia Pharmaceutical Research, LLC
    • Hendersonville, North Carolina, United States, 28739
      • Hendersonville Pharmaceutical Research
    • Raleigh, North Carolina, United States, 27607
      • North Carolina Clinical Research
    • Winston-Salem, North Carolina, United States, 27103
      • Southeastern Research Center
  • Ohio
    • Cincinnati, Ohio, United States, 45231
      • Bernstein Clinical Rsrch Ctr
    • Columbus, Ohio, United States, 43213
      • Aventiv Research Inc.
    • Dublin, Ohio, United States, 43016
      • Aventiv Research Inc.
  • Oklahoma
    • Edmond, Oklahoma, United States, 73034
      • OK Clinical Research, LLC
    • Oklahoma City, Oklahoma, United States, 73103
      • IPS Research Company
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19142
      • Arcuri Clinical Research, LLC
  • South Carolina
    • Charleston, South Carolina, United States, 29406
      • Lowcountry Lung and Critical Care
    • Easley, South Carolina, United States, 29640
      • VitaLink Research - Easley
    • Gaffney, South Carolina, United States, 29340
      • VitaLink Research -Gaffney
    • Greenville, South Carolina, United States, 29615
      • Vitalink Research
    • Rock Hill, South Carolina, United States, 29732
      • Vita Link Research- Rock Hill
    • Spartanburg, South Carolina, United States, 29303
      • Spartanburg Medical Research
    • Spartanburg, South Carolina, United States, 29303
      • South Carolina Pharma Rsrch
  • Texas
    • Houston, Texas, United States, 77058
      • Centex Studies, Inc.
    • Plano, Texas, United States, 75093
      • Advanced Clinical Research Associates
    • Sherman, Texas, United States, 75092
      • Sherman Clinical Research
    • Tomball, Texas, United States, 77375
      • DM Clinical Research
  • Virginia
    • Richmond, Virginia, United States, 23229
      • Pulmonary Associates of Richmond, Inc.
    • Richmond, Virginia, United States, 23225
      • Pulmonary Associates of Richmond, Inc.
  • Washington
    • Tacoma, Washington, United States, 98405
      • Multicare Institute for Research and Innovation
  • West Virginia
    • Morgantown, West Virginia, United States, 26505
      • Morgantown Pulmonary ClinRsrch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• All patients must sign an informed consent consistent with FDA regulations prior to participation in the trial, which includes medication washout and restrictions.

• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:

  -- Patients with a post-bronchodilator 30% ≤ Forced Expiratory Volume in one second (FEV1) <80% of predicted normal (European Coal and Steel Community( ECSC)); and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) <70% at Visit 1

• Male or female patients, 40 years of age or older.
• Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded.

• Patients must be able to perform, according to investigator's judgment, all trial related procedures including:

  • Technically acceptable pulmonary function tests (spirometry)
  • Completion of study questionnaires
• Patients must be able to inhale medication in a competent manner (in the opinion of the investigator) from the Respimat® and Diskus® inhalers and from a metered dose inhaler (MDI).

Exclusion Criteria:

• Patients with a significant disease other than Chronic Obstructive Pulmonary Disease (COPD); a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study.
• Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last 3 months prior to Visit 1 and/or between Visit 1 and Visit 2.
• Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count ≥ 600/mm3, source documentation is required to verify that the increased eosinophil count is related to a nonasthmatic condition.

Patients with any of the following conditions:

• A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists).
• A diagnosis of paroxysmal tachycardia (>100 beats per minute) (due to the known class side effect profile of ß2-agonists).
• A history of myocardial infarction within 1 year of screening visit (Visit 1).
• Unstable or life-threatening cardiac arrhythmia.
• Hospitalization for heart failure within the past year.
• Known active tuberculosis.
• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed).
• A history of life-threatening pulmonary obstruction.
• A history of cystic fibrosis.
• Clinically evident bronchiectasis.
• A history of significant alcohol or drug abuse.
• Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per the first exclusion criterion).
• Patients being treated with oral or patch β-adrenergics.
• Patients being treated with oral corticosteroid medication within 6 weeks prior to Visit 1.
• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits.
• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program.
• Patients who have taken an investigational drug within one month, six half-lives or within the wash out period (whichever is greater) prior to screening visit (Visit 1).
• Patients with known hypersensitivity to β-adrenergic drugs, BAC, EDTA, or any other component of the Respimat® inhalation solution. In addition, patients with known hypersensitivity to Lactose monohydrate (which contains milk proteins).
• Pregnant or nursing women.
• Women of childbearing potential not using a method of birth control classified at least as "acceptable". Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or post-menopausal (defined as no menses for 12 months without an alternative medical cause). Tubal ligation is NOT a method of permanent sterilisation.
• Patients who have previously been randomized in this study or are currently participating in another study.
• Patients who are unable to comply with pulmonary medication restrictions prior to randomization.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Tiotropium + Olodaterol fixed dose combination	Drug: Tiotropium; Fixed Dose Combination; Other Names: INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO; Drug: Olodaterol; Fixed Dose Combination; Other Names: INSPIOLTO, SPIOLTO, STIOLTO, VAHELVA, YANIMO
ACTIVE_COMPARATOR: Fluticasone propionate + Salmeterol fixed dose combination	Drug: Fluticasone propionate; Fixed Dose Combination; Drug: Salmeterol; Fixed Dose Combination

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment	Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 24 hours (AUC0-24) response (change from baseline) [L] after 12 weeks of treatment. FEV1 AUC0-24 was calculated as the area under the FEV1-time curve from 0-24 hours post-dose using the trapezoidal rule, divided by the duration (24 hours) and reported in liters. FEV1 AUC0-24 response (change from baseline) was defined as FEV1 AUC0-24 mius baseline FEV1.	1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline.10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min, 12h 30 min, 13h, 14h, 22h, 23h, and 24h post morning dose at week 12.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment	Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 12 hours (AUC0-12) response (change from baseline) [L] after 12 weeks of treatment. FEV1 AUC0-12 was calculated as the area under the FEV1-time curve from 0-12 hours post-dose using the trapezoidal rule, divided by the duration (12 hours) and reported in liters. FEV1 AUC0-12 response (change from baseline) was defined as FEV1 AUC0-12 minus baseline FEV1.	1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline. 10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min post morning dose at week 12.
Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment	Trough Forced Expiratory Volume in one second (FEV1) response (change from baseline) [L] after 12 weeks treatment. Trough FEV1 was defined as the mean of the FEV1 value measured at 23 hours and at 24 hours after the trial medication administration. Through FEV1 response (change from baseline) was defined as trough FEV1 minus baseline FEV1.	At 23 h and 24 h post dose at baseline and at 23h and 24 h post dose at week 12.
Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment	Peak 0-3 hours Forced Expiratory Volume in one second (FEV1) response (change from baseline) [L] after 12 weeks treatment. Peak 0-3h was defined as the maximum value measured within the first three hours post doing.	30 minutes, 1 h, 2h and 3h post dose at baseline and week 12.

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 14, 2017
• Primary Completion (ACTUAL): April 8, 2019
• Study Completion (ACTUAL): May 6, 2019

Study Registration Dates

• First Submitted: July 27, 2017
• First Submitted That Met QC Criteria: August 2, 2017
• First Posted (ACTUAL): August 7, 2017

Study Record Updates

• Last Update Posted (ACTUAL): April 16, 2020
• Last Update Submitted That Met QC Criteria: April 3, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Antagonists; Cholinergic Agents; Anti-Inflammatory Agents; Adrenergic Agonists; Dermatologic Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Anti-Allergic Agents; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Fluticasone; Xhance; Salmeterol Xinafoate; Tiotropium Bromide; Olodaterol
• Other Study ID Numbers: 1237-0063

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No